Chronic Obstructive Pulmonary Disease (COPD) refers to a group of lung diseases that block airways and make breathing difficult. It mainly includes emphysema and chronic bronchitis. Symptoms involve shortness of breath, cough, mucus (sputum) production and other lung problems. Common causes include tobacco smoking, exposure to secondhand smoke, air pollution and occupational dusts and chemicals. COPD treatment includes relievers to open airways and preventers to reduce inflammation.
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of COPD cases due to risk factors such as growing air pollution and smoking rates is one of the major drivers of the Chronic Obstructive Pulmonary Disease (COPD) treatment market growth. As per WHO data, over 329 million people suffer from COPD globally. By 2030, COPD is projected to be the third leading cause of death worldwide. The high incidence has spurred increased demand for therapeutic drugs and devices used to treat COPD symptoms and prevent exacerbations. Companies are investing heavily in developing more effective medications and technologies for COPD management to tap into this growing market opportunity.
Strength: The growing prevalence of COPD owing to rise in cigarette smoking and air pollution is driving the market growth. COPD is the third leading cause of death worldwide.
Weakness: Non-adherence to medications limits the effectiveness of treatment. Lack of awareness about the disease in developing regions is also a challenge.
Opportunity: Development of combination therapies and new biologics offer potential opportunities. Rise in healthcare expenditure in emerging markets will boost market prospects.
Threats: High cost and patents expiration of blockbuster drugs increase pricing pressure. Stringent regulations for drug approval also delays product launch.
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment market is expected to witness high growth. Chronic lower respiratory diseases, including COPD, are the third leading cause of death in the United States. The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031.
Regional analysis: North America currently dominates the COPD treatment market due to high smoking rates and growing aged population in the US and Canada. However, Asia Pacific is expected to grow at the fastest rate owing to improving healthcare facilities and rising air pollution levels in major Asian economies like China and India.
Key players: Key players operating in the COPD treatment market include First Sensor AG, Bosch Sensortec GmbH, Honeywell International Inc., Murata Manufacturing Co. Ltd., ROHM Co. Ltd., Amphenol Corporation, InvenSense Inc. (TDK Corporation), Sensata Technologies Inc., NXP Semiconductors NV (Freescale), Goertek Inc., TE Connectivity Ltd., STMicroelectronics NV, Infineon Technologies AG, Omron Corporation, and Alps Alpine Co. Ltd.
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it